ADVANCED ANALYSIS FOR PRECISION CANCER THERAPY (ADAPT)

AMENDMENT 03 is being issued to update Volume 1: Administrative & National Policy Requirements Document Template. Specifically #3 has updated footnotes and directions for content and formatting instructions. Additionally, #10 Clinical Trial Protocol and Historical Trial Accrual Rates has been added to the document (TA2 applicability). ----------------------------------------------------------------AMENDMENT 02 is being issued to clarify additional technical and phase requirements within numerous areas of the Opportunity Description. Submission requirements have changed; see Section 5 for changes. All changes are illustrated in red font; word deletions are in red font with a strikethrough (i.e., example).----------------------------------------------------------------AMENDMENT 01 is being issued to clarify technical and phase requirements within numerous areas of the Opportunity Description. All changes are illustrated in red font; word deletions are in red font with a strikethrough

(i.e., example). -----------------------------------------------------------------The mission of the Advanced Research Projects Agency for-Health (ARPA-H) is to accelerate better health outcomes for everyone by advancing innovative research that addresses society's most challenging health problems. Awardees will develop groundbreaking new ways to tackle health-related challenges through high potential, high-impact biomedical and health research. ARPA-H seeks proposals to revolutionize new adaptive strategies for treating the evolution of cancer. The ADvanced Analysis for Precision cancer Therapy (ADAPT) Program will develop an adaptive cancer treatment platform that detects when tumors change, recommends updates to the treatment plan, and evaluates revised plans through a novel clinical trial design. The ADAPT program will examine a tumor’s behavior as it changes and will then match each patient’s evolving cancer with the best available therapy. ADAPT will revolutionize cancer care by bringing new science and medicine together to map and target tumor changes that improve survival for patients with metastatic cancer. This continuous and interconnected learning process fosters rapid innovation whereby tumor biology research provides evidence that rapidly informs and shapes clinical practice.NOTE: All questions regarding ADAPT must be sent to Ask-A-Question at: https://solutions.arpa-h.gov/Ask-A-Question/